Companies Dominating the Breast Recurrence Score Test Landscape
- Genomic Health, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Agendia, Inc.
- NanoString Technologies, Inc.
- Myriad Genetics, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Roche Holdings AG
- Biotheranostics, Inc.
- Qiagen N.V.
- Veracyte, Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Agendia acquired Biomedex, a privately held molecular diagnostics company developing novel multi-cancer detection assays using liquid biopsy technology. This acquisition is expected to expand Agendia's portfolio of cancer diagnostic tests and increase its presence in the liquid biopsy market.
- Agendia received FDA approval for its ColonPrint blood test, a liquid biopsy assay that is used to detect early-stage colon cancer. This approval marks a significant milestone for Agendia as it expands its product portfolio and offers a minimally invasive option for colon cancer screening.
